832 related articles for article (PubMed ID: 31526459)
1. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
Sutandyo N; Hanafi A; Jayusman M
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
9. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
[TBL] [Abstract][Full Text] [Related]
11. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Chang HC; Wang CC; Tseng CC; Huang KT; Chen YM; Chang YP; Lai CH; Fang WF; Lin MC; Chuang HY
Thorac Cancer; 2023 Nov; 14(32):3208-3216. PubMed ID: 37737541
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
Hung LJ; Hsu PC; Yang CT; Kuo CS; Chang JW; Huang CY; Chang CF; Wu CE
Aging (Albany NY); 2024 Jan; 16(1):550-567. PubMed ID: 38194721
[TBL] [Abstract][Full Text] [Related]
13. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Gursoy P; Tatli AM; Erdem D; Goker E; Celik E; Demirci NS; Sakin A; Atci MM; Bayram E; Telli TA; Bilgin B; Bilici A; Akangunduz B; Balli S; Demirkazik A; Selçukbiricik F; Menekse S; Cavdar E; Ozturk A; Bekmez ET; Turhal S; Kilickap S; Yildirim HÇ; Oyan B; Aksoy A; Turkoz FP; Kut E; Katgi N; Sakalar T; Akyol M; Ellez Hİ; Topcu A; Erdoğan AP; Pilanci KN; Hedem E; Arak H; Akdeniz N; Alan Ö; Yapar B; Nart D; Yumuk PF
J Cancer Res Clin Oncol; 2023 Feb; 149(2):865-875. PubMed ID: 35381885
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
[TBL] [Abstract][Full Text] [Related]
15. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract][Full Text] [Related]
16. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
[TBL] [Abstract][Full Text] [Related]
17. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
[TBL] [Abstract][Full Text] [Related]
18. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B; Sendur MAN; Yucel S; Celik E; Ozyukseler DT; Ayhan M; Basoglu T; Ilhan A; Akdeniz N; Gulmez A; Dogan I; Aktas BY; Gurbuz M; Koca S; Paydas S; Tatli AM; Cinkir HY; Alan O; Erol C; Hizal M; Kut E; Menevse S; Sakalar T; Taskaynatan H; Deniz GI; Karaagac M; Avci O; Sen E; Karatas F; Akinci MB; Dede DS; Demir A; Demirkazık A; Oksuzoglu B; Kilickap S; Yumuk F; Yalcin B
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2145-2152. PubMed ID: 33433657
[TBL] [Abstract][Full Text] [Related]
19. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
Li D; Li M; Li H; Shi P; Chen M; Yang T
Dis Markers; 2023; 2023():5272125. PubMed ID: 37077340
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
